cemiplimab
regeneron
['great job', 'mmsm']
#mmsm #asco23 responses focus on itt (happy the group reported it here, great job and imp when discussion with pts) median follow up 8.4 mo 12 mo pfs is 67% 12 mo os is 79% there is results per infused also 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities